Incyclix Bio’s Promising Cancer Trial Gets New $5M Fund
Incyclix Bio secured an additional $5 million for its Series B to extend development of INX-315, a selective CDK2...
MRD Is Now the Endpoint That Matters: The EMN24 IsKia Trial Just Proved It
The EMN24 IsKia phase 3 trial didn't just test a new drug combination for newly diagnosed multiple myeloma —...
Pioneering gammaCore nVNS Study for PTSD Enrolls First Patient
electroCore’s gammaCore non-invasive vagus nerve stimulation device has entered PTSD clinical testing with the first eight of a planned...
Landmark Study Validates AI for Opioid Disorder Treatment
A peer-reviewed study in PNAS reports that GATC-1021, an AI-identified small molecule modulating 5-HT2A and 5-HT6 receptors, reduced fentanyl...
Nervgen’s Successful FDA Meeting Sparks Phase 3 Trial Hope
NVG-291 produced a mean 3.7-point gain on GRASSP Quantitative Prehension at Week 12 in chronic tetraplegia versus 0.4 points...
Fennec Pharma, U. of Arizona Cancer Center Announce Study
Fennec Pharmaceuticals is backing a new investigator-sponsored Phase I/II trial at the University of Arizona Cancer Center evaluating intravenous...
ANI Pharma Publishes ‘New Day’ Ophthalmology Trial Results
Peer-reviewed publication of the randomized Phase 4 NEW DAY trial evaluating ILUVIEN (fluocinolone acetonide 0.19 mg intravitreal implant) as...
The Basket Trial Is the New Black — and the FDA Hasn’t Caught Up
Arrowhead Pharmaceuticals' Phase 1 basket trial of zodasiran enrolled five distinct lipid disorder populations under a single protocol —...
Oral Brexanolone’s Phase 3 Failure Exposes a Gap Ketamine Already Fills
Lipocine's LPCN 1154 just failed its Phase 3 trial for postpartum depression, sending shares down 77%. For psychiatrists treating...
The FDA Just Opened a Door in Anal Cancer Trials — And Most Sponsors Don’t Know It’s There
Oncolytics Biotech's Type C meeting request to discuss a single-arm registrational pathway for pelareorep in anal cancer is more...